FDA approves Moderna’s mRNA flu vaccine
Ella Jeffries / beckershospitalreview - The FDA has approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based influenza vaccine in the U.S., for the prevention of seasonal influenza in adults ages 50 and older. The decision follows a monthslong regulatory process that included the agency’s …
AI Summary: The FDA has approved Moderna's mRNA flu vaccine, giving the familiar seasonal bug a high-tech reboot. Regulators cleared Moderna’s mRNA formulation for public use, signaling a shift toward next-generation influenza vaccines; rollout details, target groups and supply plans will follow as public health authorities coordinate distribution for the coming flu season.
- FDA's reversal and approval of Moderna mRNA flu shot (3)
- Public health guidance and flu season preparedness (3)
- What mFLUSIVA approval means for policy, coverage and mRNA (3)